Form 4: Acevedo Christopher P. reports acquisition/exercise transactions in OSTX

Rhea-AI Filing Summary

Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Acevedo Christopher P.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	100,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 100,000 shares (Direct); Common Stock — 109,375 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Acevedo Christopher P.

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MD 21638

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								109,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.34	01/22/2026		A		100,000		(1)	01/22/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

	/s/ Christopher P. Acevedo	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OS Therapies (OSTX) disclose about its CFO in this Form 4?

OS Therapies disclosed that Chief Financial Officer Christopher P. Acevedo received a grant of 100,000 stock options on January 22, 2026. The filing also shows he directly beneficially owned 109,375 shares of common stock after the reported transactions.

How many OS Therapies (OSTX) stock options were granted to the CFO?

The CFO was granted stock options to purchase 100,000 shares of OS Therapies common stock. These options were issued under a stock option award agreement and represent additional derivative securities separate from the 109,375 common shares he beneficially owned.

What is the exercise price and vesting schedule of the OSTX options grant?

The stock options have an exercise price of $1.34 per share and vest in full on the one-year anniversary of the January 22, 2026 grant date. Vesting requires that the CFO continues serving as an employee on that vesting date.

What OS Therapies (OSTX) share ownership does the CFO report after this filing?

After the reported grant, the CFO directly beneficially owned 100,000 stock options and 109,375 shares of OS Therapies common stock. The common stock position is reported as non-derivative securities, while the newly granted options are listed as derivative securities.

Is the OS Therapies (OSTX) CFO’s options grant an open-market purchase or a compensation award?

The filing describes the transaction as a grant or award, coded as an acquisition (A) of derivative securities. It is a stock option award under an agreement, not an open-market purchase of OS Therapies shares on a stock exchange.